FDA clears at‑home tDCS headset

A depression headset just crossed a line that brain-stimulation devices had not crossed before in the US. Flow Neuroscience’s Flow FL-100 is now FDA-approved for home use, not clinic use, for adults with moderate to severe major depressive disorder. That matters because brain stimulation has usually meant repeated office visits, expensive equipment, and a treatment pathway that is hard to fit into normal life. (accessdata.fda.gov) This changes the object itself — from a clinic procedure into a prescribed, remotely managed course of care. ### What is this thing, exactly? Flow FL-100 is a transcranial direct current stimulation, or tDCS, headset. Basically, it sends a very low direct electrical current through electrodes on the scalp to nudge activity in targeted brain regions. (fda.gov) In this case, the device is aimed at the dorsolateral prefrontal cortex, an area long tied to mood regulation in depression treatment research. ### What did the FDA actually approve? The approval covers adults 18 and older with moderate to severe major depressive disorder in a current episode, either as a stand-alone treatment or alongside other treatment. There is an important boundary, though — the label excludes patients considered treatment-refractory to medication. (accessdata.fda.gov) So this is not “brain stimulation for anyone with depression.” It is a narrower prescription indication with a defined patient group. ### Why is home use the real news? Because home use changes the care model more than the underlying physics. FDA’s own home-device guidance makes the point plainly — devices used outside professional facilities create different safety and usability problems. (accessdata.fda.gov) A clinic can control setup, adherence, and troubleshooting in person. A home device has to work when the patient is doing the session, following instructions, and handling the hardware away from staff. That is the hard part regulators had to bless here. ### What evidence got it through? The pivotal trial randomized 174 adults to active or sham treatment in a fully remote 10-week study. Participants did up to 36 sessions during the blinded phase. (accessdata.fda.gov) The primary result was a 2.3-point greater improvement on the HDRS-17 depression scale for active treatment versus sham at 10 weeks, with statistical significance. That is enough to make the result real, but it is not the kind of giant effect size that ends all debate. ### So is this a slam dunk? Not quite — and FDA says that in the approval materials. The agency flagged “moderate uncertainty of benefit” because of unblinding risk, no prespecified threshold for clinically meaningful HDRS-17 change, and conflicting prior literature. (fda.gov) That sounds wonky, but the plain-English version is simple: the trial was positive, yet the evidence still has some softness around how big and how robust the benefit really is. ### What does treatment look like? The headset delivers 2.0 mA stimulation and connects to a smartphone over Bluetooth. In the trial, sessions lasted 30 minutes, five times a week for 3 weeks, then three times a week for 7 more. (nature.com) The most common risks were mild and temporary — skin irritation, headache, stinging, burning, or itching — with skin burns mainly tied to improper pad use. ### Why should health systems care? Because this is not just a gadget launch. It creates a new kind of outpatient workflow — prescription, onboarding, consent, adherence tracking, side-effect monitoring, refill-like supply logistics for pads, and follow-up around a session schedule happening at home. (accessdata.fda.gov) EHRs and patient-engagement tools already adapted to remote therapy and digital therapeutics. Home neuromodulation adds another layer, but with hardware and safety controls attached. That is the bigger systems story. ### Bottom line? The breakthrough is less “electricity treats depression” — that idea has been around for years — and more “FDA is willing to let this happen in your house.” If Flow’s launch in summer 2026 goes smoothly, this could become the template for other supervised brain-stimulation treatments that move out of specialty clinics and into routine remote care. (accessdata.fda.gov) (flowneuroscience.us) (fda.gov)